和黃醫藥(00013.HK)向18名僱員授出108.6萬份認股權
格隆匯9月2日丨和黃醫藥(00013.HK)公佈,公司已於2021年9月1日授出和黃醫藥於2015年採納(經2020年4月更新)的認股權計劃項下的認股權及和黃醫藥於2015年採納的長期獎勵計劃項下的有條件獎勵。和黃醫藥向其18名僱員授出其認股權計劃項下的認股權,在承授人接納的前提下,以供認購總計108.6萬股普通股,相當於217,200份美國預託證券,認股權行使價每份美國預託證券39.74美元。
為了吸引及挽留頂尖人才,和黃醫藥的薪酬委員會已委任獨立顧問分別對美國和中國生物技術公司的同業集團進行薪酬基準研究。薪酬委員會全面審查了和黃醫藥及其附屬公司的薪酬和以股費酞基礎的奬勵政策,並且制訂具吸引力的政策,以確保集團能夠招攬和挽留頂尖人才。該政策項下以股份為基礎的奬勵的歸屬與上述同業集團者一致。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.